Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (January 2025)

25 slides from Centessa Pharmaceuticals's investor presentation, Jan 8, 2025

  1. Slide 1: January 2025 Corporate Overview

    Slide 1: January 2025 Corporate Overview

    January 2025 Corporate Overview

  2. Slide 2: Disclaimer and Forward Looking Statements

    Slide 2: Disclaimer and Forward Looking Statements

    2 DISCLAIMER AND FORWARD LOOKING STATEMENTS 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential

  3. Slide 3: Discovering and Developing Transformational Medicines for Patients

    Slide 3: Discovering and Developing Transformational Medicines for Patients

    3 Discovering and Developing Transformational Medicines for Patients OUR MISSION Centessa reported $518.4 million in cash, cash equivalents and short-term investments as of September 30, 2024. Cash runway estimated into mid-2027. Potential best-in-class / first-in-class orexin receptor 2 (OX2R) agon

  4. Slide 4: 2025 Focused Execution

    Slide 4: 2025 Focused Execution

    2025 Focused Execution ORX750 Phase 2a data in patients with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) expected in 2025 Presentation of Phase 1 data planned for Q2 2025 ORX142 Clinical data in acutely sleep-deprived healthy volunteers expected in 2025 ORX489 E

  5. Slide 5: OX2R agonists have the potential to transform the standard of care

    Slide 5: OX2R agonists have the potential to transform the standard of care

    OX2R agonists have the potential to transform the standard of care for individuals with sleep-wake, neurological, neurodegenerative and psychiatric disorders 5

  6. Slide 6: Orexin System is Implicated in Numerous Therapeutic Areas

    Slide 6: Orexin System is Implicated in Numerous Therapeutic Areas

    Orexin System is Implicated in Numerous Therapeutic Areas Orexin: a key signaling neuropeptide triggering a cascade of neurotransmitter release 6 Wakefulness Cognition Orexin (hypothalamus) Dopamine (Ventral tegmental area) Serotonin (Raphe nuclei) Acetylcholine (Basal forebrain) Sources: Pizza, F e

  7. Slide 7: Candidate Selection Criteria: Best-in-Class Profile

    Slide 7: Candidate Selection Criteria: Best-in-Class Profile

    Candidate Selection Criteria: Best-in-Class Profile • Highly potent and highly selective • Optimal predicted PK profile • Low predicted human doses • Fast onset of action OX2R agonist Orexin-A: Highly Validated Pathway Proprietary Structure Based Drug Design Pipeline of Highly Potent, Selective OX2R

  8. Slide 8: Positioned to be Potential Best-in-Class / First-in-Class in OX2R Agonist Therapeutics

    Slide 8: Positioned to be Potential Best-in-Class / First-in-Class in OX2R Agonist Therapeutics

    Positioned to be Potential Best-in-Class / First-in-Class in Emerging Category of OX2R Agonist Therapeutics ORX750 for the treatment of NT1, NT2 and IH ORX142 for the treatment of neurological, neurodegenerative and psychiatric disorders Earlier stage OX2R agonists and therapeutics for additional po

  9. Slide 9: Broad and Rapidly Advancing OX2R Pipeline

    Slide 9: Broad and Rapidly Advancing OX2R Pipeline

    Broad and Rapidly Advancing OX2R Pipeline Centessa also has multiple early-stage assets including the LockBody® Technology Platform. ASSET DISEASE/CONDITION MECHANISM PRE-CLINICAL PHASE 1 PHASE 2 ORX750 Narcolepsy Type 1 (NT1) OXR2 Agonist ORX750 Narcolepsy Type 2 (NT2) OXR2 Agonist ORX750 Idiopathi

  10. Slide 10: Potential $15B+ Market Opportunity Across Multiple Therapeutic Areas

    Slide 10: Potential $15B+ Market Opportunity Across Multiple Therapeutic Areas

    Source: Evaluate Pharma 2030 projected sales for narcolepsy – sales are not risk adjusted; projections for other disorders based on internal market research. Potential $15B+ Market Opportunity Across Multiple Therapeutic Areas Sleep-Wake Disorders NT1, NT2, IH $5B+ potential market size Additional O

  11. Slide 11: ORX750: Potential to Redefine the Standard of Care for Sleep-Wake Disorders

    Slide 11: ORX750: Potential to Redefine the Standard of Care for Sleep-Wake Disorders

    11 ORX750: Potential to Redefine the Standard of Care for Patients with Sleep-Wake Disorders Advancing Phase 2a studies in patients with NT1, NT2 and IH; Data expected across all three indications in 2025 High unmet medical need in NT1, NT2 and IH Proof-of-concept achieved and asset clinically deris

  12. Slide 12: ORX750 Interim Phase 1 Data Supports Potential Best-in-Class Profile

    Slide 12: ORX750 Interim Phase 1 Data Supports Potential Best-in-Class Profile

    ORX750 Phase 1 Interim Data Supports Potential Best-in-Class Profile for the Treatment of NT1, NT2 and IH Summary of Interim Phase 1 Data *MWT is an established registrational and objective endpoint in EDS in sleep-wake disorders. The Phase 1 clinical study of ORX750 evaluates the safety, tolerabili

  13. Slide 13: ORX750 Demonstrated Dose-Dependent Improvements in Mean Sleep Latency

    Slide 13: ORX750 Demonstrated Dose-Dependent Improvements in Mean Sleep Latency

    ORX750 Demonstrated Dose-Dependent and Significant Improvements in Mean Sleep Latency ORX750 LS Mean (95% CI) Sleep Latency (Minutes) Placebo LS Mean (95% CI) Sleep Latency (Minutes) LS Mean Difference Compared to Placebo (95% CI) p-value 1.0 mg (n=8) 18 (12, 23) 10 (4, 15) 8 (0, 16) p=0.04 2.5 mg (

  14. Slide 14: ORX750 Phase 1 Safety: Treatment-Emergent Adverse Events

    Slide 14: ORX750 Phase 1 Safety: Treatment-Emergent Adverse Events

    SAD Cohorts MAD Cohorts Placebo (n=15) ORX750 1.0 mg (n=9) ORX750 2.0 mg (n=9) ORX750 2.5 mg (n=9) ORX750 3.5 mg (n=9) ORX750 5.0 mg (n=9) Placebo (n=6) ORX750 2.0 mg (n=8) ORX750 3.0 mg (n=8) ORX750 4.0 mg (n=8) Any TEAE, n (%) 4 (27) 3 (33) 3 (33) 1 (11) 0 3 (33) 3 (50) 4 (50) 4 (50) 6 (75) Relate

  15. Slide 15: Phase 2a Study of ORX750 in NT1, NT2, IH

    Slide 15: Phase 2a Study of ORX750 in NT1, NT2, IH

    PHASE 2a STUDY Phase 2a study of ORX750 in patients with NT1, NT2, IH underway Data expected in 2025 Evaluate safety, tolerability, and PK in NT1, NT2, and IH patients Efficacy assessments will evaluate excessive daytime sleepiness using the Maintenance of Wakefulness Test (MWT)* and Epworth Sleepin

  16. Slide 16: Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750

    Slide 16: Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750

    PHASE 2a STUDY Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750 in Patients with NT1, NT2, and IH is Underway Data expected in all three indications in 2025 Innovative design with potential to enable well-powered and efficient data generation All patients to receive ORX750 for at

  17. Slide 17: OX2R Agonist Program

    Slide 17: OX2R Agonist Program

    OX2R AGONIST PROGRAM ORX750 Initiated Phase 2a study in patients with NT1, NT2, and IH; Data expected in 2025 Presentation of Phase 1 data planned for Q2 2025 ORX142 IND-enabling studies ongoing; Clinical data in acutely sleep- deprived healthy volunteers expected in 2025 ORX489 Entering IND-enablin

  18. Slide 18: LockBody Technology Platform

    Slide 18: LockBody Technology Platform

    18 LockBody Technology Platform

  19. Slide 19: LockBody Technology Platform aims to redefine immuno-oncology treatment

    Slide 19: LockBody Technology Platform aims to redefine immuno-oncology treatment

    LockBody Technology Platform aims to redefine immuno-oncology treatment Novel pharmacology combining tumor enrichment with activation of effector function Designed as single agent systemic treatment Potential wide therapeutic index1 1. LB101 in-vivo preclinical data: MC38 hPD-L1+ syngeneic model in

  20. Slide 20: Locked Configuration MOA: LockBody LB101

    Slide 20: Locked Configuration MOA: LockBody LB101

    Locked Configuration MOA LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 20

  21. Slide 21: Unlocked Configuration MOA: LockBody LB101

    Slide 21: Unlocked Configuration MOA: LockBody LB101

    Unlocked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody MOA 21

  22. Slide 22: Observed to be Well Tolerated in Non-Human Primates

    Slide 22: Observed to be Well Tolerated in Non-Human Primates

    Observed to be Well Tolerated in Non-Human Primates (NHPs) with LB101 Doses up to 50 mg/kg Source: In-vivo- LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates. No anemia/ thrombocytopenia No weight loss No change in red blood cell or hemoglobin 22 PRECLINICAL DATA

  23. Slide 23: LB101 is in a Phase 1/2a first-in-human clinical trial

    Slide 23: LB101 is in a Phase 1/2a first-in-human clinical trial

    LB101 is in a Phase 1/2a first-in-human clinical trial 23

  24. Slide 24: Discovering and Developing Transformational Medicines for Patients

    Slide 24: Discovering and Developing Transformational Medicines for Patients

    24 Discovering and Developing Transformational Medicines for Patients OUR MISSION Centessa reported $518.4 million in cash, cash equivalents and short-term investments as of September 30, 2024. Cash runway estimated into mid-2027. Potential best-in-class / first-in-class orexin receptor 2 (OX2R) ago

  25. Slide 25: Centessa

    Slide 25: Centessa

    >< CENTESSA

Source: SEC EDGAR · 8-K filed Jan 8, 2025

More decks from Centessa Pharmaceuticals PLC